Is PEN a buy according to AI stock analysis?

PEN AI stock analysis does not label Penumbra, Inc. as an automatic buy. It shows a high-quality thrombectomy franchise trading at a discount to the announced $374 Boston Scientific deal value, but the decision still depends on deal completion risk, timing, and whether a standalone re-rating would be acceptable if the transaction fails.

What is the PEN AI stock forecast?

The PEN AI stock forecast uses scenario ranges rather than a single target. A bullish case points to $355 to $374 if the acquisition closes near the announced terms, a base case sits around $315 to $350 if close slips but remains intact, and a bearish case falls toward $165 to $250 if the deal breaks and PEN re-rates as a standalone growth device name.

What technical levels matter for PEN?

The technical levels that matter for PEN are near support at $310 to $318, deeper support at $280 to $300, resistance around $335 to $350, the 52-week high near $362.41, and the $374 announced deal reference. These levels are based on the August 2026 data cutoff and should be refreshed before use.

Can AI predict PEN stock price?

No, AI cannot reliably predict stock prices. It can organize Penumbra financials, thrombectomy growth signals, valuation math, deal terms, technical levels, and risk scenarios, but future PEN returns depend on acquisition completion, regulatory outcomes, earnings, competition, market rates, and investor sentiment.

How should I use this PEN AI trading strategy?

Use this PEN AI trading strategy as a checklist for research, not as personalized advice. Confirm current price, deal status, support, resistance, filings, and hospital-demand news, then define position size and invalidation before any trade.

Why did PEN Q2 2026 earnings miss consensus?

PEN Q2 2026 diluted EPS of $0.88 came in below the roughly $1.18 consensus mainly because SG&A of $198.5 million included about $6.9 million of acquisition-related costs tied to the pending Boston Scientific deal, while revenue of $390.0 million was in line with the roughly $390 million consensus.

What does the THUNDER study add to the Penumbra story?

The THUNDER study, reported in July 2026, showed Penumbra THUNDERBOLT achieved 87.5% successful reperfusion with a 64.8% first-pass rate in 216 stroke patients across 29 U.S. centers, supporting the clinical case for its computer assisted vacuum thrombectomy platform after FDA clearance and CE Mark.

What happens to PEN if the Boston Scientific deal closes?

If the Boston Scientific deal closes on the announced terms, Penumbra stockholders receive cash, Boston Scientific stock, or a proration mix valued at $374 per Penumbra share. After close, PEN would no longer trade as an independent equity under normal standalone research assumptions.

Penumbra, Inc. research snapshot

PEN AI Stock Analysis

PEN AI stock analysis reads Penumbra, Inc. as a high-quality thrombectomy and vascular device company whose near-term stock path is still dominated by the pending Boston Scientific acquisition announced at $374 per share. At the August 2026 data cutoff, the reference quote was about $321.19 at the July 31, 2026 close, market capitalization was about $12.65 billion, and the gross deal spread versus the stated $374 consideration remained material. Q2 2026 revenue of $390.0 million was in line with expectations, but diluted EPS of $0.88 missed the roughly $1.18 consensus because of elevated operating expenses that included about $6.9 million of acquisition-related costs, and the company withheld FY2026 guidance while the deal stays pending. Business quality remains strong on double-digit revenue growth and a gross margin near 68%, but investment certainty is still deal-dependent. This page is informational research and not investment advice.

Current price

$321.19

Market cap

$12.65 billion

AI score

72 / 100

Rating

Quality thrombectomy franchise still priced as a pending strategic deal

Trend status

Deal-spread range trading below the $374 acquisition value

Data cutoff (updated monthly)

August 4, 2026

Informational use only. This page is not investment advice.

Research quality check

information Richness: A-level information richness. Penumbra has multi-year SEC filings, company earnings releases, investor materials, and broad medtech coverage, plus clear public deal terms with Boston Scientific. Q2 2026 results and THUNDER trial data were both reported during July 2026. Technical signals are secondary while the stock trades as a merger-spread name.
bias Check: The AI bias risk is anchoring on the $374 headline deal price as if close were certain. The analysis checks the reverse case: regulatory delay, deal termination, the Q2 earnings miss read-through, competitive share loss during pendency, and a re-rating if the stock returns to a standalone multiple.
ai Confidence: High data confidence
investment Certainty: Medium. Business quality and reported financials are well documented, but near-term returns depend heavily on deal completion, timing, and the cash-versus-stock election mix rather than on standalone multiple expansion alone.

Quick verdict table

Dimension	Conclusion	Confidence
Business quality	Penumbra sells thrombectomy, embolization, and access devices for stroke, pulmonary embolism, and other clot-driven vascular conditions, with FY2025 revenue of $1.40 billion and a FY2025 gross margin near 67%.	High
Moat	The moat comes from clinical familiarity with CAVT systems, a broad head-to-toe clot-removal portfolio, hospital relationships, and continuous device iteration, though Stryker, Medtronic, and other vascular peers remain intense competitors.	Medium-high
Management	Co-founder CEO Adam Elsesser has scaled the franchise since 2004 and has agreed to join the Boston Scientific board on deal close, which supports continuity but also signals a strategic exit path.	Medium-high
Financial trend	FY2025 revenue rose 17.5% to $1.40 billion with $177.7 million net income; Q2 2026 revenue rose 14.9% to $390.0 million, but diluted EPS fell to $0.88 versus about $1.18 consensus as acquisition-related costs hit SG&A.	High
Valuation	At about 79 times trailing EPS near $4.07, the standalone multiple is expensive, but the stock also trades at a clear discount to the announced $374 deal value.	Medium
Technical trend	Price action is mainly a deal-spread range between recent lows near the low $310s and resistance toward the $335 to $350 zone, not a pure fundamentals breakout.	Medium
Risk level	Risk is moderate to high because deal failure, regulatory delay, competition, product or clinical setbacks, and medtech multiple compression can all reprice the equity quickly.	Medium-high
AI confidence	High for reported financials and public deal terms, medium for close timing, and lower for standalone long-term multiple assumptions after a deal break.	High data confidence
Investment certainty	Medium certainty for business quality, but no automatic buy signal because the dominant decision variable is deal completion risk versus spread capture.	Medium

PEN AI stock forecast

PEN AI Stock Forecast Scenarios

The PEN AI stock forecast mixes the announced Boston Scientific deal path with a standalone earnings framework. These are conditional ranges, not guaranteed targets. The deal path matters more while the transaction remains pending; the standalone path matters if the deal fails or is revised.

Bullish case

$355 to $374

More likely if the Boston Scientific transaction closes on the stated $374 cash-and-stock terms, regulatory and stockholder conditions clear, and residual merger spread compresses into the deal value.

Base case

$315 to $350

More likely if the deal stays intact but close timing slips later into 2026, leaving a still-open spread while Penumbra continues mid-teens revenue growth and a gross margin near 68%.

Bearish case

$165 to $250

More likely if the acquisition is delayed, revised, or terminated, and the market re-rates PEN as a standalone premium medtech name with slower growth, deal-cost hangover, or multiple compression.

PEN AI technical analysis

PEN AI Technical Analysis

PEN AI technical analysis as of the August 2026 cutoff should be read through a merger-spread lens. The stock sits well below the $374 deal value and below the 52-week high near $362.41, while remaining far above the 52-week low near $221.26. Classic moving-average signals matter less than deal news, regulatory updates, and spread compression.

Level	Value	Why it matters
Current price	$321.19	Jul 31, 2026 close per stockanalysis.com; use live quotes before any trading decision.
Near support	$310 to $318	Recent trading has repeatedly tested the low $310s while the deal remains pending.
Deeper support	$280 to $300	A break below $300 would widen the deal spread sharply and could signal rising termination or delay fears.
Near resistance	$335 to $350	Spread compression often stalls in the mid $340s until clearer close catalysts appear; Citi holds a $350 target.
Deal reference	$374 announced consideration	Boston Scientific agreed to value each Penumbra share at $374 in cash or BSX stock subject to proration; this is not a market price target by itself.
52-week high	$362.41	StockAnalysis and other quote pages list this as the recent high, still below the full $374 deal value.
52-week low	$221.26	The low remains a useful stress reference if the deal thesis fails.
Momentum	Range-bound / deal-driven	Day-to-day momentum is more sensitive to M&A headlines than to ordinary earnings-season technicals.
Volume	Moderate relative to float	Liquidity is adequate for research monitoring, but event-driven spikes are common around regulatory or close updates.
Volatility	Elevated deal-spread volatility	The 52-week range of about $221 to $362 shows that position sizing matters even when a headline deal price exists.
Invalidation	Sustained close below $300 or formal deal break	Either signal would force a reset from merger-spread analysis back to standalone valuation and growth quality.

PEN AI trading strategy

PEN AI Trading Strategy Framework

The PEN AI trading strategy is a rules-based research framework, not personalized advice. For most investors the key choice is whether they are underwriting deal close, trading residual spread, or analyzing Penumbra as a standalone medtech compounder.

Trend-following setup

Treat sustained closes above $340 with rising volume and constructive deal headlines as evidence that the market is pricing a higher close probability toward the $374 reference.

A close back below $310, adverse regulatory news, or a revised deal structure should invalidate the close-probability thesis.

Mean-reversion setup

If PEN retests $310 to $318 without a fundamental thesis break and without a formal deal scare, compare the pullback with cash balances, the Q2 revenue run-rate, and public deal-status updates.

Do not average down unless maximum loss, event risk, and holding period are defined before entry. Merger arb can gap on binary news.

Fundamental monitor

Track U.S. thrombectomy growth, embolization and access growth, gross margin near 68%, free cash flow, deal-related expense drag, and Boston Scientific regulatory or closing disclosures.

Reduce confidence if revenue growth stays solid but free cash flow, hospital demand, or deal certainty deteriorates.

Investment research summary

Four-master Research Compression

Business essence

Customers pay Penumbra for devices that remove blood clots and manage complex vascular conditions, especially ischemic stroke, pulmonary embolism, and acute limb ischemia, with speed and procedural control as the value proposition.

Moat

The moat is strongest where CAVT product design, physician training, hospital inventory habits, and a broad neuro plus peripheral portfolio reinforce one another. THUNDER data for THUNDERBOLT published in July 2026 support the clinical case, but it is not an unassailable monopoly against large diversified device peers.

Munger risk inversion

The thesis fails if the Boston Scientific deal collapses, if competitors reclaim thrombectomy share, if product or clinical setbacks damage trust, or if investors refuse a premium multiple once PEN is again valued as a standalone name.

Management

Founder-led management has built a multi-product vascular franchise and guided the company into a strategic sale process. Capital allocation is now largely deal-constrained rather than open-ended, and the Q2 2026 SG&A line already carries acquisition-related costs.

Industry trend

Mechanical thrombectomy and broader vascular intervention remain long-duration healthcare trends driven by aging populations, clot disease prevalence, and procedure expansion outside the U.S., but the field is regulated and competitive.

Valuation and margin of safety

At about $321 versus a $374 deal value, the market already embeds meaningful close risk. Margin of safety is not free: investors are paid a spread only if the deal closes as expected, and they face a large re-rating risk if it does not.

Source-backed data

PEN Data Table

Every metric below includes a source and last verification date.

Metric	Value	Source	Last verified
PEN price	$321.19 at the July 31, 2026 close	StockAnalysis PEN quote	August 2, 2026
Market cap and shares	About $12.65 billion market cap, roughly 39.39 million shares outstanding	StockAnalysis PEN statistics	August 2, 2026
Announced acquisition terms	Boston Scientific to acquire Penumbra at $374 per share, about $14.5 billion enterprise value, cash and stock with proration, expected to close in 2026	Boston Scientific and Penumbra joint announcement	August 2, 2026
Q2 2026 revenue	$390.0 million, up 14.9% year over year; thrombectomy $259.0 million, embolization and access $131.1 million	Penumbra Q2 2026 results release	August 2, 2026
Q2 2026 earnings	$41.0 million operating income, $34.8 million net income, $0.88 diluted EPS versus roughly $1.18 consensus	Penumbra Q2 2026 results release	August 2, 2026
Q2 2026 gross margin and expenses	Gross margin 67.9%; total operating expenses $223.9 million, including $6.9 million of acquisition-related costs in SG&A	Penumbra Q2 2026 results release	August 2, 2026
Q2 2026 balance sheet	$205.3 million cash and equivalents plus $453.5 million marketable investments; $442.7 million inventories	Penumbra Q2 2026 balance sheet	August 2, 2026
FY2025 revenue and net income	Revenue $1,403.7 million, up 17.5%; net income $177.7 million; diluted EPS $4.52 GAAP	Penumbra FY2025 results release	August 2, 2026
FY2025 product mix	Thrombectomy $947.9 million; embolization and access $455.7 million	Penumbra FY2025 results release	August 2, 2026
THUNDER study results	THUNDERBOLT met its performance goal: 87.5% successful reperfusion (mTICI 2b-3), first-pass rate 64.8%, median time to revascularization 20 minutes	Penumbra THUNDER study release	August 2, 2026
THUNDERBOLT regulatory status	U.S. FDA clearance received June 11, 2026 and CE Mark in Europe received June 15, 2026	Penumbra press releases	August 2, 2026
Trailing valuation markers	About 79x trailing EPS near $4.07; forward PE about 57; roughly 8.5x book value near $37.9 per share	StockAnalysis PEN valuation ratios	August 2, 2026
Analyst consensus	Hold rating with an average price target of $361.58 across 16 analysts; target range $320 to $374	S&P Global via StockAnalysis	August 2, 2026
52-week range	$221.26 to $362.41	StockAnalysis PEN quote	August 2, 2026

Frequently Asked Questions

Compare BSX AI stock analysis Read MDT AI stock forecast Explore SYK AI technical analysis View PODD AI trading strategy Explore the AI Stock Picker Build an AI trading strategy

This PEN AI stock analysis is an informational research tool. It is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of August 2026 and can be wrong if Penumbra results, the Boston Scientific transaction, product safety, competition, valuation multiples, or market conditions change.